A 10-year-old boy comes to the emergency department for evaluation of right knee pain. The child's guardians stated that he had been complaining of knee pain for the past 4 days and it had been getting progressively worse. There was no history of trauma. The day before the visit the boy developed a fever, and over the past day he has become increasingly lethargic. On physical examination blood pressure was 117/75 mm Hg,  HR 138 bpm, temperature 38.1 C (100.5 F), respiration 28 bpm, oxygen saturation 97%. There was edema and tenderness of the right thigh and knee, as well as effusion and extremely limited range of motion. Sensation and motor tone were normal. Plain radiography and CT showed an osteolytic lesion.

eligible ages (years): 0.0-999.0,  All  Kidney Cancer Sarcoma Diagnosis of peripheral primitive neuroectodermal tumor, including peripheral neuroepithelioma or Askin tumor OR Diagnosis of localized or metastatic Ewing's sarcoma, including the following: Unresectable or metastatic small cell osteosarcoma Unresectable or metastatic other nonrhabdomyosarcomatous soft-tissue sarcomas Unresectable or metastatic other non-osteosarcomatous bone sarcomas Desmoplastic small round-cell tumor Metastatic or non-metastatic Wilms' tumor Immunocytochemistry, electron microscopy, and/or chromosomal analysis may be required to rule out other small round cell neoplasms Age: Any age Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified PRIOR Not specified


eligible ages (years): 0.0-999.0,  All  Neuroblastoma Sarcoma Histologically confirmed GD2 positive tumors which High risk neuroblastoma (stage IV, or N-myc amplified, or localized neuroblastoma multiply recurrent) Recurrent or metastatic osteosarcoma Recurrent or metastatic GD2 positive sarcomas If free of disease, patient must be fully recovered from toxic effects or complications of prior treatments (chemotherapy or surgery) No greater than 6 months since last chemotherapy or surgery before first injection of A1G4 Age Any age Performance status Not specified


eligible ages (years): 0.0-999.0,  All  Sarcoma Histologically confirmed recurrent osteosarcoma after initial systemic therapy with doxorubicin Measurable disease Immunohistochemical evidence of 2+ overexpression of HER2 Age Any age Performance status Karnofsky 80-100% Life expectancy Not specified Hematopoietic


eligible ages (years): 16.0-999.0,  All  Lung Cancer Adult Soft Tissue Sarcoma Colorectal Cancer Bone Cancer Ovarian Sarcoma Melanoma Colon Cancer Rectal Cancer Breast Cancer Eye Cancer Uterine Sarcoma ENTRY --Disease Characteristics- Histologically documented metastatic cancer of one of the following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell lung cancer Breast carcinoma Sarcoma HLA-Cw*0702 positive MAGE-12 expression by RT-PCR amplified tissue analysis Failed prior standard therapy Measurable or evaluable disease No renal carcinoma Hormone receptor status: Not specified --Prior/Concurrent Therapy- Biologic therapy: At least 3 weeks since prior biologic therapy for cancer No other concurrent biologic therapy for cancer Chemotherapy: At least 3 weeks since prior chemotherapy for cancer and recovered No concurrent chemotherapy for cancer Endocrine therapy: At least 3 weeks since prior hormonal therapy for cancer No concurrent hormonal therapy for cancer No concurrent steroids Radiotherapy: At least 3 weeks since prior radiotherapy for cancer and recovered No concurrent radiotherapy for cancer Surgery: Prior surgery for cancer allowed --Patient Characteristics- Age: 16 and over Sex: Male or female Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 90,000/mm3 Hepatic: Bilirubin no greater than 1.6 mg/dL AST/ALT less than 3 times normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No cardiac ischemia, myocardial infarction, or cardiac arrhythmias (if receiving interleukin-2 (IL-2) therapy) Pulmonary: No obstructive or restrictive pulmonary disease (if receiving IL-2 therapy) Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No active systemic infections No autoimmune disease, known immunodeficiency disease, or active primary or secondary immunodeficiency Hepatitis B surface antigen negative HIV negative No other active major medical illnesses (if receiving IL-2 therapy)


eligible ages (years): 2.0-21.0,  All  Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Kidney Cancer Leukemia Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Meets 1 of the following Histologically confirmed solid tumor (closed to accrual as of 10/4/2007) that relapsed after or failed to respond to front-line curative therapy and for which no other potentially curative treatment options exist Curative therapy may surgery, radiotherapy, chemotherapy, or any combination of these modalities Eligible tumor types but are not limited to, the following Rhabdomyosarcoma Other soft tissue sarcomas Ewing's sarcoma family of tumors Osteosarcoma Neuroblastoma Wilms' tumor


eligible ages (years): 18.0-999.0,  All  Arthritis Septic Patients with acute onset of symptoms of less than or equal to two weeks' duration Patients with infection of only the following joints: ankle, knee, hip, wrist, elbow, or shoulder Patients with proven bacterial infection by positive gram stain or culture of synovial fluid and with white blood cell count in synovial flood consistent with infection (75,000 000 cells/mm3.) Cases with negative synovial fluid cultures if positive blood cultures are present and associated with typical inflammatory synovial fluid changes without other identifiable sources of infection and if antibiotic therapy had been initiated earlier to explain negative synovial fluid cultures Monoarticular arthritis  Gonococcal infections Infected prosthetic joints Adjacent osteomyelitis preceding joint infection Septic arthritis occurring as an incidental event late in the course of otherwise fatal illness Patients that are 17 years old or less Polyarticular arthritis


eligible ages (years): 18.0-75.0,  All  Thromboembolism Knee Replacement Hip Replacement Patients undergoing either an elective major hip or knee replacement or revision Signed written informed consent. Men or women of non-child bearing potential(i.e., post menopausal or with hysterectomy of bilateral tubule ligation) or women of childbearing potential without any plan to have a child  History of serious active bleeding in last 3 month Concurrent or history of thrombocytopenia ( Platelet< 100x109/L) History of hypersensitivity reaction to heparin, Low molecular weight heparin or pork product Acute bacterial endocarditis Congenital or acquired bleeding disease in last 3 months Concurrent uncontrolled ulcer or gastrointestinal disease with blood vessel dysplasia Concurrent hemorrhagic cerebrovascular disease or surgical history in cerebral, spine or eye Conditions need to leave a tubule in intradural or extradural Contraindication to anticoagulant or condition required to take long term oral anticoagulant Abnormality in hepatic (>1.5x UNL), renal (Clcr < 30ml/min) or cardiac function, uncontrolled hypertension or tumor Concurrent disorder of blood vessel in lower limb


eligible ages (years): 50.0-999.0,  All  Knee Osteoarthritis Aged 50 years or over of either gender Radiographic tibiofemoral OA grade 2 or higher, unilateral or bilateral Demonstrated knee OA related dysfunction per WOMAC score Not engaged in a regular exercise program for minimum of 6 months  Inability to obtain physician release for exercise High risk health status e.g., uncontrolled medical conditions such as hypertension, diabetes, heart disease, pulmonary disease, high cholesterol, anginal type pain, dizziness or syncope, orthopnea or paroxysmal nocturnal dyspnea, ankle edema, heart palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue or shortness of breath with usual activities Unresolved balance disorder Unresolved neurological disorder History of knee surgery or major knee trauma injury Hip or ankle instability, excessive weakness, surgery or major trauma injury Intra-articular joint injection within 4 weeks of the study


eligible ages (years): 16.0-999.0,  All  Edema knee replacement surgery  pacemaker cardiac defibrillator other metallic implant than knee arthroplasty


eligible ages (years): 18.0-45.0,  All  Familial Mediterranean Fever Fulfilling the Tel Hashomer for the diagnosis of FMF [5] Suffering from episodes of exertional leg pain and or exertional ankle edema 18-45 years old On a stable (≥ 2 weeks) dose of oral colchicine therapy Non-smokers  with known peripheral vascular disease (PVD) and/or multiple risk factors for PVD (such as diabetes, hypertension, hyperlipidemia) Suffering from muscular or neurological diseases not related to FMF With elevated serum creatinine / liver enzymes/ creatine phosphokinase (CPK) levels Suffering from claustrophobia, or with metal fragments in body tissue, or with other contraindications for MRI


eligible ages (years): 18.0-80.0,  All  Osteoarthritis Male or female subjects aged between 18 and 80 years inclusive Subjects who require a primary total knee replacement and are considered by the Investigator to be suitable for the specific knee prosthesis identified in the protocol Subjects who are able to give and have given voluntary, written informed consent to participate in this clinical investigation Subjects who have given consent to the transfer of his/her information to DePuy Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups  Subjects who have a pre-operative limb deformity of equal to or greater than 10° varus or 15° valgus as defined using the anatomical axis Subjects who have a fixed flexion contracture of greater than 10º Subjects who are clinically obese i.e. BMI ≥30 Subjects who have, in the opinion of the Investigator, an existing condition that would compromise their participation and follow-up in this study Female subjects who are pregnant or lactating Subjects who are known drug or alcohol abusers or have a psychological disorder that could affect follow-up care or treatment outcomes Subjects who have participated in a clinical investigation with an investigational product in the last 3 months Subjects currently involved in any personal injury litigation, medical-legal or worker's compensations claims Subjects who have previously had a prosthetic knee replacement device (any type) of the affected knee Subjects who present with ankylosis of the hip joint on the side to be treated or previous ipsilateral Upper Tibial Osteotomy/High Tibial Osteotomy


eligible ages (years): 0.0-21.0,  All  Neuroblastoma Melanoma Osteosarcoma Ewing Sarcoma Diagnosis Part A: Recurrent or refractory neuroblastoma or melanoma Part B: Recurrent or refractory neuroblastoma or melanoma Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma Age: ≤ 21 years of age at the time of enrollment (i.e. participants are eligible until they reach their 22nd birthday) Does not have a clinically significant neurologic deficit or objective peripheral neuropathy (greater than or equal to grade 2). Peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowed Life expectancy: at least 8 weeks Organ Function: Must have adequate organ and marrow function Performance status: Karnofsky ≥ 50 for > 10 years of age; Lansky ≥ 50 for children < 10 years of age Prior Therapy: Patient must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study  Prior monoclonal antibody: Participants having received in vivo monoclonal antibodies for biologic therapy or for tumor imaging are eligible provided they did not experience a severe allergic reaction with the antibody Pregnancy or Breast Feeding: Study participants who are pregnant are not eligible for this study. Pregnancy tests must be obtained in girls who are > 10 years of age or post-menarchal within 7 days prior to study enrollment. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during participation in the trial. Breast feeding should be discontinued if a mother wishes to participate in this study Allergy: known hypersensitivity to other recombinant human antibodies An uncontrolled infection


eligible ages (years): 18.0-90.0,  All  Reduced Knee Flexion Reduced flexibility in AROM of knee extension Pain that is worsened by bending over while legs are straight Impaired gait pattern Ability to understand informed consent and experiment responsibilities  Fractures Knee sepsis Osteomyelitis or any orthopedic infection Extensor mechanism dysfunction Psoriasis Knee joint neuropathy Previous Stroke or Brain Injury


eligible ages (years): 18.0-999.0,  All  Total Knee Arthroplasty Knee Pain Primary, bilateral TKA Age 18 years or older Postoperative analgesic pain includes bilateral continuous femoral nerve blocks  Chronic, high-dose opioid use History of opioid abuse Any neuro-muscular deficit of either femoral nerves and/or quadriceps muscles Pregnancy Incarceration


eligible ages (years): 1.0-50.0,  All  Osteosarcoma Age > 1 year and < 50 years First osteosarcoma relapse, either local or metastatic, or second relapse after exclusive surgery NB: Whenever possible, only patients with histological evidence of relapse will be included Indication for chemotherapy confirmed by a multidisciplinary committee Surgical resection of all tumor sites must be possible, either as first-line therapy or after chemotherapy Lansky score ≥ 60%, or ECOG Performance Status ≤ 2 ≥ 21-day interval after first-line chemotherapy Blood tests, renal and liver functions within the normal range for age with, in particular, 7 days prior to study entry, blood or serum values as follows blood: neutrophil count > 1 G/L; platelets >100 G/L renal: serum creatinine ≤ 1.5 x ULN depending on age; patients with serum creatinine values > 1.5 x ULN are eligible if creatinine clearance is > 70 mL/min/1.73 m² liver: total bilirubin < 2 x ULN; ASAT and ALAT ≤ 5 x ULN  Patients with multiple relapses for whom surgical resection seems impossible, even after chemotherapy Patients already treated with high-dose chemotherapy regimens Patients with a contra-indication to the treatment proposed Patients not eligible for leukapheresis Two-year follow-up impossible due to social, family, geographic or psychological reasons Patient included in another protocol of clinical research Pregnant or lactating women


eligible ages (years): 40.0-76.0,  All  Osteoarthritis of the Knee Subject voluntarily agrees to participate in this study and signs an IRB-approved informed consent prior to entry into the Screening Period (Day -3) Subject has OA pain of the Target Knee with a WOMAC Pain Subscale baseline value of > 9 at the Baseline/Randomization Period (Maximum score is 20 for 5 questions with 0 = none; 4 = extreme Subject must have a Functional Capacity Classification of I-III Subject has taken a stable dose of NSAIDs or COX-2 inhibitor agents for OA pain for at least 22 of the previous 28 days and for each of the 2 days prior to the Screening Period (Day -3) and for at least each of the 2 days prior to the Baseline/Randomization Period (Day 1). Subject must also, agree and be expected to remain on this stable daily dose throughout the study Subject is between 40-75 years of age Diagnosis of OA is present for at least 6 months according to the ACR for OA of the knee Radiographic evidence of OA of the Target Knee (within the last 3 years) with a Kellgren-Lawrence scale of 2 or 3 Subject is generally in good health Subject is expected to be compliant with study procedures Females of child-bearing potential must have a negative urine pregnancy test at Screening  Presence of tendonitis, bursitis, partial or complete joint replacement of Target Knee Presence of active skin disease, erythema, infection, wound or irritation near the treatment area of the Target Knee Subject has history of frequent headache or other painful conditions (other than OA) that is expected to require any use of systemic opiates or derivatives, or more than twice a week additional administration of different oral NSAIDs or COX-2 inhibitors (see Section 6.1, Table 2) Subject experiences regular significant pain due to osteoarthritis or other conditions in the non-target knee or other joints while on stable doses of their current analgesic therapy Subject has an anticipated need for any surgical or other invasive procedure that will be performed on the Target Knee or other part of the body during the course of the study OA secondary to local joint disorders (e.g., mechanical disorder, internal derangement of the knee), systemic metabolic disease, endocrine disorders, bony dysplasia, calcium crystal deposition disease, neuropathic arthropathy, frostbite, congenital abnormalities Subject has history and/or diagnosis of rheumatoid arthritis, fibromyalgia, connective tissue disease, psoriatic arthritis, erosive inflammatory OA, diffuse idiopathic skeletal hyperostosis, severe neurologic or vascular disease Subject has active (redness, swelling, fever, etc.) gout/pseudogout within 6 months prior to screening Subject has Type I or Type II diabetes with peripheral neuropathies Subject is extremely obese with BMI ≥ 39


eligible ages (years): 21.0-999.0,  All  Dengue Fever Age ≥ 21years Probable or confirmed dengue a) Confirmed dengue: laboratory confirmation of acute dengue by either i) positive polymerase chain reaction (PCR) for viral ribonucleic acid (RNA), or ii)positive NS1 antigen test with a compatible clinical syndrome b) Probable dengue: Positive acute dengue serology and clinical presentation fulfilling either WHO 1997 or 2009 for probable dengue i) 1997 Acute febrile illness and two or more of the following headache retro-orbital pain myalgia arthralgia rash hemorrhagic manifestations


eligible ages (years): 18.0-999.0,  All  Urinary Incontinence Subject is a male IC user able to self-catheterise Subject has used hydrophilic-coated ICs for at least 1 month Subject is at least 18 years old Subject has provided informed consent  Subject has symptoms of UTI (ie, fever, autonomic dysreflexia, spasticity, discomfort or pain over the kidney or bladder, onset/increase in incontinence episodes, cloudy urine with increased odour, malaise, lethargy, or sense of unease) Subject has known abnormalities in the lower urinary tract


eligible ages (years): 0.0-999.0,  All  Sarcoma Diagnosis of localized or metastatic osteosarcoma Banked snap-frozen tumor tissue samples and paired blood DNA samples available Not specified Not specified


eligible ages (years): 18.0-75.0,  All  Healthy Healthy males or females  Abdominal surgery other than appendectomy, laparoscopic cholecystectomy, cesarean section, vaginal or laparoscopic hysterectomy or tubal ligation A history of chronic gastrointestinal or systemic illnesses that could affect gastrointestinal motility Any history of hypertension Use of medications that may alter gastrointestinal motility or interact with the study medications Use of any of the study medications within the past 30 days Pregnancy Chronic renal insufficiency (serum creatinine >1.5 mg/dL) Psychiatric or psychologic dysfunction


eligible ages (years): 18.0-999.0,  All  Joint Disease Patient is of legal age and skeletally mature Patient requires primary total knee arthroplasty due to non inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, a vascular necrosis, dysplasia/DDH) or inflammatory joint disease (e.g., Rheumatoid arthritis) Patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, haematological, etc., conditions that would pose excessive operative risk The patient will be available for follow up throughout the duration of the study  Patient is unable to have an MRI scan due to the following conditions Cardiac pacemaker Surgical clips in head (aneurysm clips) Some artificial heart valves Electronic inner ear implants Metal fragments in eyes Electronic stimulators Implanted pumps Patient has active infection or sepsis (treated or untreated) Patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery


eligible ages (years): 15.0-30.0,  All  Knee Instability The anterior drawer laxity of the knee joint in this study was defined as anterior displacement over 3 mm discrepancy between bilateral knee joints by a KT-2000 test under 20-pound force  anterior displacement less than 3 mm discrepancy between bilateral knee joints by a KT-2000 test under 20-pound force


eligible ages (years): 18.0-999.0,  All  Osteoarticular Infections Patient are more than 18 years old Patient who do not declined to have his medical records reviewed for research Spondylodiscitis (S) group Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context. Spinal biopsies will be justified by one or more clinical or imaging findings Clinical presentation Spinal pain unrelieved by rest Localized tenderness, Neurological deficits or limited range of motion Fever > 38°C Imaging findings (plain radiographs, MRI or CT) Erosions of end plates on adjacent vertebral bodies  Patients already include Patient without health insurance Antibiotic treatment before sampling does not constitute an criterion for control groups Patient with one or more Suspicion of concomitant infection defined by a fever >38°C and CRP > 10mg/l Arthrosis treated by infiltration in the 6 months which preceding Rapidly progressive arthrosis Prosthesis loosening or bone necrosis presumed to be aseptic Patients with prior spinal instrumentation or surgery


eligible ages (years): 18.0-999.0,  All  Overactive Bladder Women >18 years of age A score of > 4 on the OAB-q short form for urgency (question 1) Average urinary frequency > 10 times in one 24 hour day based on a 3-day voiding diary Self-reported bladder symptoms present > 3 months Self-reported failed conservative care (e.g., dietary restriction, fluid restriction, bladder training, behavioral modification, pelvic muscle training, biofeedback, etc.) or use of antimuscarinics Off all anti-muscarinics for at least 2 weeks prior to enrollment Capable of giving informed consent Ambulatory and able to use a toilet independently, without difficulty Capable and willing to follow all study-related procedures  The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) The patient has an active urinary tract infection Neurogenic bladder Botox use in bladder or pelvic floor muscles in the past year Pacemakers or implantable defibrillators Primary complaint of stress urinary incontinence Current vaginal infection Current use of InterStim Current use of Bion Current use of TENS in the pelvic region, back or leg


eligible ages (years): 2.0-35.0,  All  Osteosarcoma Lung Metastases Must be between 2 and 35 years of age at time of diagnosis Must have biopsy-proven, high-grade osteosarcoma Patients with metastases are eligible as long as the lung is the only site of metastatic disease The primary tumor and all pulmonary metastases must be deemed to be potentially resectable. There must be a commitment by the surgical team to resect the primary tumor at week 12, and pulmonary nodules at any point, unless the clinical situation indicates these interventions are not in the patient's best interest Patients must have normal laboratory values and cardiac function as defined below Creatinine clearance or radioisotope GFR of > or equal to 70ml/min/1.73 m2 OR A serum creatinine based on age/gender as follows Age Maximum Serum Creatinine (mg/dL) Male Female month to < 6 months 0.4 0.4 6 months to < 1 year 0.5 0.5 to < 2 years 0.6 0.6  Patients with any low-grade osteosarcoma, post-radiation osteosarcoma, and osteosarcoma associated with Paget's disease are not eligible Patients with metastases other than lung metastases are not eligible Patients may not have received prior chemotherapy


eligible ages (years): 45.0-79.0,  All  Knee Osteoarthritis A female is eligible if she is of Non-child bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is at least 2 year after post menopausal Child bearing potential and agrees to the acceptable contraceptive methods used consistently and correctly Pregnancy test result of negative at screening Primary Knee OA(Osteoarthritis) on medial femorotibial compartment based on ACR(American College Rheumatology) Criteria ACR : With Knee pain and satisfied at least 1 of 3 (① age > 50 years, morning stiffness < 30 minute, ③ Presence of Crepitus and Osteophytes on motion) Appropriately signed and dated informed consent has been obtained  Rheumatoid arthritis or inflammatory arthritis Bilateral total knee replacement already treated, or planning for the procedure Knee prosthesis already implanted, or foreseen within the next year Clinically significant hip osteoarthritis Severe renal insufficiency defined as creatinine clearance < 30ml/mln(Cockcroft formula) Clinically significant pulmonary, hepatic, renal or heart disorder or diagnosis crucial disease by investigator ( Glycosuria(Diabetes mellitus) or asthma patients are excluded from this clinical study and the patients who has a clinically significant disease are also excluded.) MRI contraindications : overweight, inferior limb diameter non-fitting the knee antenna, inserted pace-maker, metallic prosthesis( if known to interfere with MRI procedure or if known to be unsafe for MRI), metallic clips, insulin pump, cytostatic pump, hearing aid, essential tremor, claustrophobia, etc Allergic reaction to Clinical trial medication Other clinical trial drugs during the 1 month prior to the screening visit


eligible ages (years): 0.0-999.0,  All  Arthrogryposis Craniofacial Abnormalities Syndrome Group Freeman-Sheldon syndrome Sheldon-Hall syndrome Distal arthrogryposis type 1, or Distal arthrogryposis type 3 Deceased patients with enough clinical information available to satisfy study requirements Syndrome Group  Individuals not confirmed to have a condition under study Deceased patients without enough clinical information available to satisfy study requirements Patients with other anomalies, not having one of the above syndromes Patients or parents of minor children not willing to give consent Mature female patients who are pregnant or breast-feeding will be reassessed for consideration for enrolment Mature female patients who are currently experiencing menses will be reassessed for consideration for enrolment Patients with active, acute comorbid illness will be reassessed for consideration for enrolment Control Group Subjects must be healthy and free of active disease Subject or parent of minor child must be willing to give consent


eligible ages (years): 18.0-999.0,  All  Linear or Emi-linear Incisions Total Hip Arthroplasty Total Knee Arthroplasty Subject must be ≥ 18 years of age Subject must, at the treating physician's determination and definition, be an appropriate Candidate for primary total hip or knee arthroplasty Subjects who undergo primary total knee or hip arthroplasty must have a linear or semi-linear incision whose length and curvature should fit within the dimensions bound by the polyurethane foam (10 inches in length by 2.5 inches in width) Subject is able and willing to provide written informed consent and comply with visit schedule Subject must agree to avoid application of tanning lotions or exposure of ultraviolet radiation from sun or artificial sources such as a tanning bed on operative area for the duration of study participation Subject must not be pregnant if of child-bearing potential, or otherwise must be surgically sterilized or unable to conceive. All females, regardless of child-bearing potential, will receive a urine hCG test 2 weeks prior to surgery and the test result must be negative for pregnancy Subjects who are of child-bearing potential must be utilizing an acceptable method of birth control (eg, birth control pills, condom with spermicide, diaphragm with spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc) and be willing to continue birth control for duration of study participation. If birth control method is the form of birth control pills, shots, implants skin patches, or IUD, the method must have been utilized for at least 30 days prior to study participation Subject must be willing to wear loose fitting clothing for duration of treatment period Subject must be willing to comply with visit schedule for the duration of the study  Positive pregnancy test confirmed by hCG in urine Current or past (30 days prior to surgery) within time of screening attempts to become pregnant Current local or systemic infection (eg, skin infections, sinus infections, urinary tract infection, sepsis, etc) Current or past (14 days prior to surgery) within time of screening topical treatments on operative area (eg, laser hair or tattoo removal, sunless tanning lotions) Current or past (14 days prior to surgery) steroid topical therapies on operative area Current or past (30 days prior to surgery) use of oral steroids (NOTE: Use of non-topical, ophthalmic or aerosol types of steroids (ie, inhaled corticosteroids) are permitted at screening and throughout the clinical trial) Current or past (72 hours prior to surgery) within surgery use of antihistamines Current or past (30 days prior to surgery) within time of screening use of oral Tetracycline or AcutaneTM or topical Tetracycline or AcutaneTM on the operative area Presence of skin lesions or abnormalities on operative area Current or past malignancy requiring immunosuppressant therapy or chemotherapy within 5 years within time of screening


eligible ages (years): 18.0-75.0,  All  Arthroscopic Meniscal Surgery Male and female patients between 18 and 75 years of age Good general health condition Signed written informed consent Patients with necessity for arthroscopic meniscal surgery Ensured compliance of subject over the whole study period  Concomitant or previous participation in a clinical investigation within the last 3 months prior to study inclusion Knee joint arthroscopy in study relevant joint within 6 months prior to study inclusion Patients with known hypersensitivity to the investigational device (i.e. active compound and excipients) or any component or procedure used in the study Contraindication for the use of the investigational product or for the scheduled arthroscopy, used anesthesia and post-surgical treatment Concomitant disease of sufficient severity (e.g. uncontrolled diabetes mellitus, carcinoma, etc.), which in the opinion of the investigator, may put the patient at risk when participating in the study, or affect the patient's ability to take part in the study Concomitant disease of sufficient severity at study relevant joint (e.g. known or suspected infection, peripheral neuropathy or presence of hemarthros) List of concomitant medications not allowed which interfere with the functional assessments of this study Use of medication contraindicated for arthroscopic surgery Intra-articular treatment with a sodium hyaluronate-based product within the last 6 months or use of corticosteroid containing substance within the last 3 months at study relevant joint Recent history of drug and/or alcohol abuse (within the last 6 months) or patients with severe mental illness or suicidal tendency


eligible ages (years): 18.0-99.0,  All  Urinary Incontinence includes English-speaking women over the age of 18 who have been admitted to the Rehabilitation Institute of Chicago with reports of urinary incontinence in the past 3 months. Those who report "yes" to the screening questions who fit the above will be screened by the principal investigator to ensure they fall into the criteria  Non-English speaking women under the age of 18, or those that do not give consent to participate in the study will not be enrolled. Also excluded will be any woman who has any chance of being pregnant or having an active urinary tract infection. No women with active infection lesions, unknown vaginal bleeding or those who have never had any kind of pelvic examination will be included in the study. Other women with a neurogenic bladder or admission FIM scores on sections Comprehension and Memory of below 4. Women with reports of significant pelvic pain or recent pelvic surgery or radiation or post-partum in last 6 months will be excluded


eligible ages (years): 2.0-4.917,  All  Influenza Healthy male or female child at least 24 months of age and no older than 59 months of age at the time of study vaccination A child whose parent or guardian's primary residence, at the time of study vaccinations, is within the Kamalapur surveillance site catchment area and who intends to be present in the area for the duration of the trial A child whose parent or legal guardian is willing to provide written informed consent prior to the participant's study vaccination  Has any serious chronic disease including progressive neurologic disease, tuberculosis, Down's syndrome or other cytogenetic disorder, or known or suspected disease of the immune system Is receiving immunosuppressive agents including systemic corticosteroids during the two weeks prior to study vaccination Has a history of documented hypersensitivity to eggs or other components of the vaccine (including gelatin, sorbitol, lactalbumin and chicken protein), or with life-threatening reactions to previous influenza vaccinations Is receiving aspirin therapy or aspirin-containing therapy currently or two weeks before Lives in household with somebody currently participating in a respiratory vaccination or antiviral study Has current or past participation (within 2 months of trial enrollment visit) in any clinical trial involving a drug or biologic with activity against respiratory disease Has any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the child


eligible ages (years): 18.0-75.0,  All  Irritable Bowel Syndrome Age 18-75 years Positive for IBS symptoms by Rome III No prior abdominal surgery (except appendectomy or cholecystectomy Score of 10 or less on either Anxiety or Depression on the Hospital Anxiety/Depression Inventory  Patients with significant depression (score of greater than 10 on Hospital Depression Inventory Patients with anxiety (score of greater than 10 on Hospital Anxiety Inventory. However, patients on stable doses of selective serotonin inhibitors (SSRIs) or low dose of tricyclic antidepressants will be eligible


eligible ages (years): 0.0-39.0,  All  Localized Osteosarcoma Metastatic Osteosarcoma Recurrent Osteosarcoma Tissue samples from patients with osteosarcomas obtained from the CHTN P9754 clinical trial for patients with non-metastatic osteosarcoma AOST0121 clinical trial for patients with metastatic or recurrent osteosarcoma


eligible ages (years): 0.0-999.0,  All  Osteosarcoma Samples from the COG tissue repository


eligible ages (years): 0.0-999.0,  All  Sarcomas Procurement Diagnosis of refractory or metastatic GD2-positive sarcoma not responsive to standard treatment. Patients with osteosarcoma do not require GD2 testing of their tumor as osteosarcomas are uniformly GD2 positive Either previously infected with varicella zoster virus(VZV; chicken pox) or previously vaccinated with VZV vaccine Karnofsky/Lansky score of greater than or equal to 50 Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent Treatment Diagnosis of refractory or metastatic GD2-positive sarcoma not responsive to standard treatment. Patients with osteosarcoma do not require GD2 testing of their tumors as osteosarcomas are uniformly GD2 positive Recovered from the acute toxic effects of all prior chemotherapy Karnofsky/Lansky score of greater than or equal to 50 Bilirubin less than or equal to 3x upper limit of normal, AST less than or equal to 5x upper limit of normal, Serum creatinine less than or equal to 2x upper limit of normal, Hgb greater than or equal to 9.0 g/dl, ANC>500/uL, platelets > 50,000/uL  Procurement • Known primary immune deficiency or HIV positivity Treatment Severe intercurrent infection Known primary immune deficiency or HIV positivity Pregnant or lactating History of hypersensitivity reactions to murine protein-containing products Known allergy to VZV vaccine


eligible ages (years): 18.0-30.0,  All  Hyperalgesia Asymptomatic subjects who met the criterion of being between 18 and 30 years old  rheumatologic diseases or any type of cancer, cervical surgery in the past, whiplash trauma and undergoing any type of treatment like physical therapy, manual therapy, osteopathy, chiropraxis, acupuncture during the last three months. All patients recruited for the study complained of pain localized in the neck and/or head region. Initial screening was accomplished by telephone and eligible persons attended a evaluation appointment development of systemic or degenerative diseases subjects with symptoms of depression according Beck's questionnaire pain in any area between the lower back and head in the last 9 months traumatic event in the past 12 months history of neck or face pain in the last 6 months


eligible ages (years): 18.0-999.0,  All  Septic Arthritis Major patients hospitalized in Rheumatology, Infectiology, Orthopedy Department (hospital of Nantes, of La Roche sur Yon and of Saint-Nazaire) with a septic arthritis of shoulder, or elbow, or wrist , or hip, or knee, or ankle on native joint, with positive microbiologic culture joint fluid or positive hemoculture; the diagnosis was based on positive histology or imagery with an inflammatory joint fluid if the microbiologic cultures (hemoculture or joint effusion) were negative  Presence of material on the targeted joint Age < 18 years old Patients under guardianship Pregnancy


eligible ages (years): 50.0-999.0,  All  Total Knee Arthroplasty Pain Nerve Blocks Age > 50 years Patients set to cemented Total knee arthroplasty in spinal block Patients who have given written informed consent to participate in the study after having understood the contents of the protocol and limitations fully Illness score 1-3  Patients who can not cooperate with the investigation Patients who do not understand or speak Danish Patients receiving immunosuppressive therapy Patients with a treatment-dependent diabetes mellitus Patients with known neuropathy in the lower limbs Allergy to those drugs used in the study Alcohol and / or drug abuse the investigator's opinion Patients who can not tolerate Non steroid analgesic drugs Use of strong opioid several times a day (morphine, ketogan, Oxynorm, methadone, fentanyl)


eligible ages (years): 45.0-80.0,  All  Osteoarthritis Pain Age 45 to 80 years old, inclusive Clinical diagnosis of osteoarthritis in one target knee based on the following American College of Rheumatology (ACR) Knee Pain At least 1 of 3 Age > 50 years Morning stiffness lasting < 30 minutes Crepitus on motion Osteophytes on radiograph Symptoms associated with osteoarthritis of the knee (including pain) for ≥ 6 months prior to Screening Knee pain associated with osteoarthritis, which required NSAID or other therapy for ≥ 15 days during the preceding month  General Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential may not be entered into the study if They are or intend to become pregnant (including use of fertility drugs) during the study They are nursing They are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the 9-week clinical trial.) Body Mass Index (BMI) over 40 A history of osteoarthritis symptoms that are completely non-responsive to non-steroidal anti-inflammatory drugs (NSAIDs) at the discretion of the Investigator Planned change (increase or decrease) in subject's level of physical activity (e.g., aerobic or anaerobic exercise) during the 6-week Treatment Period following randomization Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01 or OLT1177-02


eligible ages (years): 1.0-35.0,  All  Sarcoma Osteosarcoma Neuroblastoma Melanoma Diagnosis (a) Osteosarcoma, neuroblastoma and melanoma that have been treated with standard frontline therapy and are judged to be incurable with standard therapy, based upon the fact that they are unresectable, metastatic, progressive/persistent or recurrent Evaluable disease must be present i) For all histologies except osteosarcoma and neuroblastoma, pathologic review of frozen tissue must document GD2+ expression. Positive expression is defined as at least 2+ expression (0-4+ scale) in > 50 percent of the tumor cells using anti-GD2 mAb 14G2a. If adequate archived frozen tissue is available, this may be utilized, or if not, patients may undergo biopsy following enrollment to obtain tissue to assess GD2 expression, with the following restrictions ii) Patients with histologies other than osteosarcoma or neuroblastoma must have adequate accessible tumor for biopsy (at least 1 cm diameter) iii) Procedures employed to acquire biopsies for tumor lysates will be limited to percutaneous needle or core biopsies, thoracoscopic excision or open biopsies of readily accessible lesions. Pulmonary lesions may be biopsied but extensive surgery such as thoracotomy or laparotomy should not be employed iv) Patients who will require biopsy should not be enrolled if in the opinion of the principal investigator, the tumor site places the patient at substantial risk from the biopsy procedure Weight greater than or equal to 15 kg Age less than or equal to 35 years old at the time of enrollment Prior Therapy  Concurrent Illnesses Clinically significant systemic illness (e.g. serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgment of the PI would compromise the patient s ability to tolerate protocol therapy or significantly increase the risk of complications Peripheral nerve symptoms from prior therapies or from tumor compression > grade 1 Untreated CNS metastasis Extradural masses that have not invaded the brain parenchyma or parameningeal tumors without evidence for leptomeningeal spread will not render the patient ineligible. Patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible Prior Therapy Previous treatment with genetically engineered GD2-CAR T cells. Previous vaccine therapy, anti-GD2 mAb therapy or therapy with other genetically engineered T cells is not an Lactating or pregnant females (due to risk to fetus or newborn) Active HIV, HBV or HCV infection Immune Therapies


eligible ages (years): 5.0-12.0,  All  Cerebral Palsy age 5 to12 years inclusive assessed as GMFCS Levels II or III able to follow testing instructions, and participate in a minimum of 30 minutes of active PT able to reliably signal pain, fear and discomfort have passive range of motion (ROM) of hips and knees within minimum range requirement for Lokomat (hip and knee flexion contracture < 10 degrees, and knee valgus < 40 degrees) client of Child Development Program at Holland Bloorview able to commit to attendance of twice weekly for eight weeks (to support the primary efficacy analysis)  a fixed knee contracture > 10 degrees, knee valgus >40 degrees such that robotic leg orthosis will not be adaptable to lower limbs hip instability/subluxation > 45% orthopaedic surgery within the last 9 months (muscle) or 12 months (bone) Botulinum toxin-A (BTX-A) injections to lower limb in the last 4 months inability to discontinue BTX-A for period of 6 months (during trial) due to concerns about ROM or pain severe spasticity may be a contraindication any weightbearing restrictions seizure disorder that is not controlled by medication (if on medication, must not have had a seizure in the last 12 months) open skin lesions or vascular disorder of lower extremities not able to co-operate or be positioned adequately within the Lokomat as shown during the two Lokomat fitting/acclimatisation sessions


eligible ages (years): 18.0-65.0,  All  TBI Traumatic Brain Injury Age > 18 years Brain injured patients with a diagnosis of NHO around the hip and/ or knee for a period of greater than one year Patients who are able, or legal guardians who are willing, to provide informed consent after both oral and written information  Pregnancy Rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures Elevated serum alkaline phosphatase (SAP) levels and/or evidence of active bone remodelling in bone scan


eligible ages (years): 16.0-65.0,  All  Osteochondral Lesion of Talus Degenerative Lesion of Articular Cartilage of Knee single osteochondral lesion in knee/ankle (2-4 sq cm)  multiple osteochondral lesions pre-existing injuries/arthropathies


eligible ages (years): 50.0-100.0,  All  Peripheral Nerve Block Pain Age> 50 years Patients set to cemented Total knee arthroplasty in spinal block ASA 1-3  Patients who can not cooperate with the investigation Patients who have given written informed consent to participate in the study after having understood the contents of the protocol and limitations fully Patients who do not understand or speak Danish Patients receiving immunosuppressive therapy Patients receiving glucocorticoid daily Patients with a treatment-dependent diabetes mellitus Patients with known neuropathy in the lower limbs Allergy to those used in the study drugs Alcohol and / or drug abuse the investigator's opinion


eligible ages (years): 18.0-999.0,  All  Osteoarthritis of Hip Osteoarthritis, Knee Planned primary unilateral THA or TKA Patients (male/female) ≥ 18 år Patients giving written informed consent and authority Patients receiving spinal anaesthesia  Patients with intolerance to trial medications Rejection of or contraindicated spinal anaesthesia Patients with rheumatoid arthritis Patients with Body Mass Index (BMI) ≥ 35 Patients that do not read or write Danish


eligible ages (years): 16.0-40.0,  All  Primary Hypertrophic Osteoarthropathy diagnosed with primary hypertrophic osteoarthropathy clinically over 16 years old no other medication intake informed consent signed  below 16 years old active gastric ulcer inflammatory bowel disease New York Heart Association classification（NYHA） II to IV liver or renal failure allergic to nonsteroid anti-inflammatory drugs not willing to participate


eligible ages (years): 1.0-49.0,  All  Recurrent Osteosarcoma Patients must have had histologic verification of osteosarcoma at original diagnosis or relapse Patients must have measurable disease according to 1.1, and have relapsed or become refractory to conventional therapy Patient must have archival tumor specimen available for submission Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea) Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation Monoclonal antibodies: must not have received any monoclonal based therapies within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within 2 weeks, prior to study enrollment Must not have received other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study enrollment  Patients with > grade 2 neuropathy according to the Modified ("Balis") Pediatric Scale of Peripheral Neuropathies will be excluded except in cases in which neuropathy is secondary to prior surgery Patients who have previously received glembatumumab vedotin (CR011-vcMMAE; CDX-011) or other monomethyl auristatin E (MMAE)-containing agents Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin; compounds of similar composition auristatin PHE as an anti-fungal agent, auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and symplostatin 1 as an anti-tumor agent Female patients who are pregnant are ineligible Lactating females are not eligible unless they have agreed not to breastfeed their infants Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation All patients and/or their parents or legal guardians must sign a written informed consent All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met


eligible ages (years): 1.0-6.0,  All  Caudal Block Patients aged 1-6 years, classified as American Society of Anesthesiologist (ASA) 1 and 11 who are undergoing herniotomy and whose parents or legal guardian has duly signed an informed consent form  Patients with hypersensitivity to any local anesthetics Children with Bleeding diathesis Presence of Infections at puncture sites Preexisting neurological disease Patients with diabetes mellitus Failure to consent by parents


eligible ages (years): 1.083-40.0,  All  Recurrent Osteosarcoma Patients must have recurrent high-grade OS verified by histopathology review by MSKCC's Department of Pathology Patients must be in a ≥2nd complete remission as indicated by appropriate radiologic evaluations at the time of study entry Patients must be older than 1 year of age and less than or equal to 40 years of age Prior therapy: ≥3 weeks should have elapsed since last cytotoxic therapy, immunotherapy or radiation therapy. More than one week should have elapsed since major surgery Adequate hematopoietic function defined as Absolute neutrophil count ≥ 500/ul Absolute lymphocyte count ≥ 500/ul Platelet count ≥ 50,000/ul (transfusion independent) Adequate hepatic function as defined by Total bilirubin of ≤ 1.5 times upper limit of normal (exception is made for patients with Gilbert's syndrome who may be considered eligible if total bilirubin is ≤ 3 times upper limit of normal)  Patients with OS in first complete remission Presence of overt metastatic disease at any site Active life-threatening infection Pregnant women or women who are breast-feeding Inability to comply with protocol requirements


eligible ages (years): 0.0-999.0,  All  Infection Immune Deficiency Hypogammaglobulinemia Septic Arthritis Mycoplasma Hominis Adult with decision making capacity afflicted with chronic mycoplasma hominis septic arthritis despite standard treatments


eligible ages (years): 18.0-999.0,  All  Periprosthetic Joint Infection Septic Arthritis adult of 18 or more years written consent to participate in study suspicion of septic arthritis or periprosthetic joint infection joint aspirate minimum of 5 ml  is not able to understand the aim or purpose of this study empty joint aspirate


eligible ages (years): 0.0-999.0,  All  Childhood Solid Tumor for the safety and feasibility testing of AV0113 Male and female patients with a malignant neoplasia shall be eligible for this protocol provided they have no more "conventional" treatment options and have measurable disease. There is no age limit for participation in this study provided that the tumour is typical for the group of refractory solid neoplasias of childhood Patients must not be HIV-positive Patients must have primary tumour tissue or cells available at sufficient number to allow treatment according to the protocol Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form for patients included in the long-term follow up and comparison with historic controls Patients suffering from bone or soft tissue sarcoma that received treatment with AV0113 or are documented in the database of the Medical University Vienna's Department of Orthopaedics At least one disease recurrence after first CR or worse disease condition (e.g.: never reached CR) Diagnosis between 1992-2003 and/or "inclusion time point" during the years 2000-2004 Availability of date of death or of confirmation that patient is still alive (for the currentness of confirmation that patients are still alive only the time span from 1 April 2014 to 1 April 2015 is accepted)  for the safety and feasibility testing of AV0113 Any of the not met Any condition which, in the investigator's opinion, may pose a risk to the patient or will interfere with the study objectives for patients included in the long-term follow up and comparison with historic controls Date of "inclusion time point" and death or confirmation that patient is still alive at time of evaluation not available


A 28 yo female G1P0A0 is admitted to the Ob/Gyn service for non-ruptured ectopic pregnancy. Past medical history is remarkable for obesity, a non-complicated appendectomy at age 8, infertility treatment for the past 3 years, and pelvic laparoscopy during which minor right Fallopian tube adhesions were cauterized. Her LMP was 8 weeks prior to admission. Beta HCG is 100 mIU. The attending physician usually treats unruptured ecoptic pregnancies laparoscopically but is concerned about the patient's obesity and history of adhesions.

eligible ages (years): 0.0-999.0,  All  Ectopic Pregnancy Confirmed diagnosis of ectopic pregnancy via D&E without products of conception identified on frozen pathology or VABRA without products of conception identified with pathologic evaluation or Ultrasound visualization of a gestational sac in the adnexa, with definitive visualization of a yolk sac or fetal pole the subject is hemodynamically stable without signs of hemoperitoneum laparoscopy has not been performed the subject is able to return for frequent follow-up care normal renal and liver function have been documented within 2 days normal white blood count and platelet count have been documented as per laboratory standard normal chest x-ray was obtained if the subject has a history of pulmonary disease  breastfeeding laboratory evidence of immunodeficiency alcoholism or chronic liver disease the concomitant use of non-steroidal anti-inflammatory drugs blood dyscrasia such as leukopenia, thrombocytopenia, or severe anemia active pulmonary disease hepatic, renal, or hematological dysfunction adnexal mass > or = 3.5 cm presence of fetal cardiac motion active major psychiatric disorder such as major depression, bipolar disease, psychotic disorder, or drug addiction


eligible ages (years): 21.0-40.0,  All  Infertility Female partner age 21 up to 40th birthday, at the time of recruitment. Infertility is defined as failure to conceive a recognized pregnancy after one year (or 12 menstrual cycles) of unprotected intercourse Male partner has a normal semen analysis with a sperm concentration of >15 million total motile sperm, >1% normal forms by strict or >5 million total motile sperm on IUI prep Female patient has at least one ovary and at least one ipsilateral patent fallopian tube confirmed by HSG or laparoscopy; pelvic pathology amenable to operative laparoscopy (pelvis restored to functional). The open tube cannot have had a previous ectopic (tubal) pregnancy and the closed tube cannot be a hydrosalpinx (a tube that is blocked at the end and filled with fluid), unless a tubal ligation has been performed at the junction of the uterus and fallopian tube Patients with surgically corrected stages I and II endometriosis will be included Normal uterine cavity demonstrated by HSG, Sonohysterogram (SHG), or hysteroscopy; pathologies of uterine cavity amenable to operative hysteroscopy (cavity restored to normal and demonstrated by post operative study) Anovulatory patients who did not conceive after a minimum of three ovulatory cycles with any medications, not including gonadotropin therapy. Anovulatory patients unable to achieve ovulation at dosages up to 150 mg of clomiphene or standard dosages of other ovulation inducing medications (i.e. bromocriptine). Hypoestrogenic hypothalamic amenorrhea patients will qualify immediately for prior to any gonadotropin therapy Normal ovarian reserve demonstrated in all patients i.e., cycle day 3 FSH/E2 values of <15 mIU/mL and <100 pg/mL, respectively. Normal TSH and prolactin Female body mass index ≤ 38  Previous tubal reconstructive surgery in which the pelvis was not restored to functional Unilateral or bilateral hydrosalpinx (a tube that is blocked at the end and filled with fluid) that has not had a tubal ligation performed at the junction of the uterus and fallopian tubes A laparoscopy that demonstrated pelvic adhesions or endometriosis for which the pelvis could not be restored to normal by surgery or endometriosis was not ablated or excised. All patients with stages III and IV endometriosis One or more prior ectopic pregnancies in which one or both tubes were rendered nonfunctional; two or more ectopic pregnancies, even if tubes are patent Severe male factor (i.e.; semen analysis with a sperm concentration of <15 million total motile sperm, <1% normal forms by strict or <5 million total motile sperm on IUI prep). Couples using donor semen will be excluded Previous treatment with IUI or IVF. Previous treatment of normal ovulation patients with gonadotropins Inadequate ovarian reserve demonstrating FSH >15 mIU/mL or estradiol > 100 pg/mL Patients requiring gamete intrafallopian tube transfer (GIFT), zygote intrafallopian tube transfer (ZIFT), or tubal embryo transfer (TET) Female body mass index > 38


eligible ages (years): 18.0-80.0,  All  Elective Laproscopic Bilateral Inguinal Hernia Elective Laproscopic Cholecystectomy Local ethic committee approval Written informed consent ASA physical status I-III, scheduled for elective laparoscopic cholecystectomy and elective laparoscopic BIH  Difficulty in communication Allergy to oxycodone and/or morphine Allergy to local anesthetic History of alcohol and substance abuse Treated depression Chronic use of opioid or tramadol or Pregnancy Obstructive sleep apnea Anticipated fiber optic intubation Severe hepatic or renal impairment


eligible ages (years): 18.0-45.0,  All  Bilateral Ovarian Disease Female patients aged 18-45 years at screening Patients undergoing elective laparoscopic surgery due to known or suspected bilateral ovarian disease  Pregnant (including ectopic pregnancy) or breastfeeding patient Patients with a documented diagnosis of cancer Patients with a lymphatic, hematologic or coagulation disorder Patients with a known or suspected hypersensitivity to blood, blood products or any constituent of Adhexil™ Patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants Patients who have participated in another clinical study within 30 days of enrolment Investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study


eligible ages (years): 11.0-21.0,  All  CHLAMYDIA INFECTIONS Female to 21 years of age at the time of enrollment Positive for Chlamydia infections by urine or cervical PCR h Chlamydia-negative subject who fits all other Negative pregnancy test Written informed consent provided Signed a HIPAA authorization form Willingness to comply with all the requirements of the protocol  Positive pregnancy test Negative for Chlamydia, unless 5th negative subject to be in the control group Any condition that in the opinion of the investigator would interfere with the ability of the potential subject to complete the study or would result in significant risk to the subject


eligible ages (years): 21.0-24.0,  All  Chlamydia Trachomatis Infertility Ectopic Pregnancy born in 1974, 1974 or 1976 AND living in Aarhus County October 1007


eligible ages (years): 18.0-45.0,  All  Ovarian Cysts Endometriosis Adhesions Female patients aged 18-45 years at screening Patients undergoing elective laparoscopic surgery involving at least one adnexa  Pregnant (including ectopic pregnancy) or breastfeeding patient Patients with a documented diagnosis of cancer Patients with a lymphatic, hematologic or coagulation disorder Patients with a known or suspected hypersensitivity to blood, blood products or any constituent of Adhexil™ Patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants Patients who have participated in another clinical study within 30 days of enrolment Investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study


eligible ages (years): 20.0-90.0,  All  Adhesive Capsulitis shoulder discomfort for at least one month limited range of motion of the glenohumeral joint in at least two directions  systemic inflammatory joint disease radiological evidence of bony abnormality of the shoulder full-thickness rotator cuff tear acute systemic medical illness history of major trauma or surgery involving the shoulder contraindication to intra-articular, local anesthestic injection


eligible ages (years): 21.0-45.0,  All  Unplanned Pregnancy Currently pregnant with a single gestation of at least 27 completed weeks estimated gestational age, with no complications of pregnancy including, but not limited to, preeclampsia, non-gestational diabetes, anemia Desires to use intrauterine contraception (IUD) after delivery Anticipates having a vaginal delivery No intention to leave the area 7 months after enrollment Able to consent to participate in the study in English Has no known uterine anomalies Has no allergies to any components of the intrauterine contraception  Prior cesarean delivery Having been treated for pelvic inflammatory disease within 3 months prior to the start of the pregnancy Allergic to betadine Allergy to lidocaine Medical or personal conditions which in the judgment of study staff contradict participation in the study Any contraindications to use of the levonorgestrel-releasing intrauterine contraceptive system which includes: known or suspected breast carcinoma, acute liver disease or liver tumor, history of ectopic pregnancy, cervical cancer or carcinoma in situ After enrollment, and after delivery of the infant but before IUD insertion subjects will be excluded by checking with the attending obstetric physician and/or obstetric medical chart for the following Endometritis or chorioamnionitis during the intrapartum period Membranes ruptured for greater than 24 hours prior to delivery Fever greater than or equal to 38C


eligible ages (years): 18.0-60.0,  All  Clinically Severe Obesity Gastroesophageal Reflux Disease Status post, either open or laparoscopic, primary Nissen fundoplication with all the following requirements Met NIH for bariatric surgery With functional or failed antireflux surgery (Nissen fundoplication) Laparoscopic approach for revisional surgery  Any other type of revisional bariatric procedure Nonstandard revisional RYGB surgery Open approach for revision surgery Missing records and/or unreachable patients with scant information for analysis


eligible ages (years): 18.0-999.0,  All  Morbid Obesity The last 800 consecutive patients in the surgical practice of Drake Bellanger and Andrew Hargroder who had a laparoscopic sleeve gastrectomy The last 800 consecutive patients in the surgical practice of Drake Bellanger and Andrew Hargroder who had a laparoscopic gastric bypass  Subjects having any other obesity surgical procedure


eligible ages (years): 18.0-45.0,  All  Contraception Intrauterine Devices Pilot Study Africa Primary Ages 18-45 attending prenatal care Greater than 34 weeks estimated gestational age Desire to use the CuT380A-IUCD for contraception postpartum Plan to stay in the area for at least 5 months postpartum If HIV+ the women must be WHO Clinical Stage 1 or 2, or known to be clinically well on antiretroviral therapy as documented in their health passport No prior cesarean delivery No treatment for pelvic inflammatory disease within 3 months prior to pregnancy No known uterine anomalies No known pelvic tuberculosis  prior cesarean section fever during labor and delivery AIDS, not well on antiretroviral therapy genital tuberculosis known uterine abnormalities or genital tract cancer history of ectopic pregnancy within 3 months of current pregnancy


eligible ages (years): 18.0-60.0,  All  Morbid Obesity Age: 18 years BMI 35-39.9 kg/m2 with one or more severe co-morbid conditions or BMI 40-55 kg/m2 Willingness to comply with dietary restrictions required by the protocol History of obesity for at least 5 years History of at least 6 months of documented failures with traditional non-surgical weight loss methods Willingness to follow protocol requirements which signing the informed consent form, completing routine follow-up visits for the study duration, and completing all pre and post-operative laboratory and diagnostics tests in addition to the quality of life questionnaire If female with childbearing potential, using an appropriate form of contraception  Age less than 18, age greater than 60 Pregnancy History of major depressive disorder or psychosis Previous bariatric surgery or previous gastric surgery Presence of achalasia Any condition that, in the judgment of the investigator, would place a subject at undue risk, or could potentially compromise the results or interpretation of the study


eligible ages (years): 15.0-40.0,  All  Ectopic Pregnancy Criteria:The criterion was the presence at transvaginal ultrasound of an extraovarian adnexal mass in women with a suspected ectopic pregnancy (amenorrhea, bleeding and pain) with positive test for beta-hCG  The criterion was non-tubal ectopic pregnancy (cervical, cesarean scar, ovarian, and abdominal)


eligible ages (years): 29.0-38.0,  All  Endometriosis Infertility Infertility Mild endometriosis (until stage II)  ovarian endometrioma > 2 cm FSH > 12 mIU/ml Mail factor infertility


eligible ages (years): 18.0-40.0,  All  Cesarean Section; Complications Placenta Previa Placenta Accreta Singleton pregnancy Term (> 37 weeks) pregnancy Cervical dilatation < 4 cm Kerr incision Age > 18 years old  Being in active phase of labor Emergency situations (fetal distress, cord prolapse, placental abruption,severe pre-eclampsia, eclampsia, placenta previa, vasa previa ) Having a history of uterine surgery (myomectomy, hysterotomy) other than CS Extension of Kerr incision Multiple pregnancy Maternal diabetes mellitus Maternal connective tissue disease Uterine malformation Uterine fibroids on Kerr incision line Chorioamnionitis


eligible ages (years): 12.0-55.0,  All  Ectopic Pregnancy pregnant females in 1st trimester present to emergency department complaint of abdominal/pelvic pain or vaginal bleeding  previous ultrasound diagnostic of location of pregnancy


eligible ages (years): 20.0-36.0,  All  Endometriosis Patient with minimal-mild endometriosis recently treated by laparoscopy with a waiting period of 6 to 12 months following the procedure No other infertility factors Normal serum basal hormone levels as well as documented ovulation  Moderate or severe endometriosis Dense adnexal and/or ovarian adhesions due to pelvic inflammatory disease or previous pelvic surgery Age more than 36 years, BMI more than 30 kg/m2 women with a previous pregnancy


eligible ages (years): 39.0-65.0,  All  Obesity Insulin Resistance Diabetes Mellitus Type 2 No major organ disease Fasting blood glucose < 126 mg/dL BMI 25-35 kg/m2 Nonpregnant/nonlactating  pregnancy/lactation major organ disease drugs that influence insulin resistance unstable body weight or active weight loss program outside BMI range or age range diabetic by fasting glucose 126 mg/dL or higher


eligible ages (years): 20.0-40.0,  All  Polycystic Ovary Syndrome Chinese women with PCOS. PCOS must have been diagnosed based on the presence of two of the following three Rotterdam : (1) oligomenorrhea, anovulation; (2) hyperandrogenism; and (3) the observation of polycystic ovaries by sonography. Oligomenorrhea is defined as an intermenstrual interval >35 days or <8 menstrual bleedings in the past year. Amenorrhea is defined as an intermenstrual interval >90 days History of at least one year of infertility Age between 20 and 40 years old Normal semen analysis based on World Health Organization (2010). The husband did not need to sign the consent form because semen analysis is part of the clinical assessment at the sites. A sperm concentration ≥15 × 106/mL and total motility ≥40% in the semen analysis of the husband was required for the woman to be included Normal uterine cavity and at least one tube patent upon hysterosalpingography or HyCoSy  History of significant system diseases such as heart, lung, or kidney diseases History of other endocrine disorders Use of hormonal therapy, including metformin, in the past 3 months Previous sterilization procedures (vasectomy or tubal ligation) that have been reversed


eligible ages (years): 18.0-65.0,  All  Obesity Subject is willing to give consent and comply with evaluation and treatment schedule 18 to 65 years of age (inclusive) Have a BMI > 27 with one or more significant co-morbid medical conditions which are generally expected to be improved, reversed, or resolved by weight loss. These conditions may but are not be limited to - Hyperlipidemia Type 2 diabetes Mild obstructive sleep apnea Hypertension Osteoarthritis of the hip or knee Agree to refrain from any type of weight-loss drug (prescription or OTC) or elective procedure that would affect body weight for the duration of the trial HbA1C < 11%  Previous malabsorptive or restrictive procedures performed for the treatment of obesity Scheduled concurrent surgical procedure, with the exception of SOC liver biopsy Women of childbearing potential who are pregnant or lactating at the time of screening or at the time of surgery Any condition which precludes compliance with the study History or presence of pre-existing autoimmune connective tissue disease Use of prescription or over the counter weight reduction medications or supplements within thirty days of the Screening Visit or the duration of study participation Psychiatric disorders that may affect compliance with the clinical trial, including dementia, active psychosis, severe depression requiring > 2 medications, or history of suicide attempts. Any condition which places the subject at undue risk for the procedure (surgeon's discretion)


eligible ages (years): 20.0-65.0,  All  Obesity Weight Loss Diet Age (years): 20-65 Body Mass Index (kg/m2): 28-35 Non-smokers  Subjects using prescription medication, or suffering from diseases or conditions that might influence the outcome of the study: this concerns diseases/medication that influence body weight regulation (malabsorption, untreated hypo/hyperthyroidism, eating disorders, systemic use of steroids, etc.) and obesity-related cardiovascular risk factors (heart disease, systolic and diastolic blood pressures > 160/100 mmHg, blood glucose > 6.1 mmol L-1, blood cholesterol > 7 mmol L-1, blood triglycerides > 3 mmol L-1) marked alcohol consumption > 21 alcoholic units week-1 (male), or >14 alcoholic units week-1 (female) planned major changes in physical activity during the study to an extent that might interfere with the study outcome as judged by the investigator blood donation within the past 2 months prior to the study weight change of >3 kg within 2 months prior to the study psychiatric disease (based on medical history only) pregnant or lactating women, or women planning to become pregnant within the next 12 months surgically treated obesity participation in other clinical studies within the last 3 months drug abuse (based on clinical judgment)


eligible ages (years): 19.0-39.0,  All  Polycystic Ovarian Syndrome Age > 18 years but < 40 years old Was diagnosed PCOS Normal husband's seminal fluid analysis (SFA)  Not having medical problems eg renal disease, tyhroid disorder, hyperprolactinemia, liver disease Other causes of anovulatory infertility


eligible ages (years): 18.0-50.0,  All  Ectopic Pregnancies Patients with pregnancy of unknown location (PUL) diagnosed 22 days after oocyte retrieval, at first ultrasound routine control (A "pregnancy of unknown location" (PUL) is a term used to classify a women with a positive pregnancy test and an empty uterus with no signs of an intrauterine or extrauterine pregnancy on a transvaginal ultrasound scan.) Patients with Intrauterine pregnancy : Viable intrauterine pregnancy (IUP) An intrauterine gestational sac containing a fetal pole with visible cardiac activity Patients with Ectopic pregnancy (Tubal ectopic pregnancy): An empty endometrial cavity with: (i) an inhomogeneous adnexal mass or (ii) an empty extrauterine gestational sac seen as hyperechoic ring or (iii) an extrauterine gestational sac with a yolk sac and/or fetal pole with or without cardiac activity


eligible ages (years): 18.0-46.0,  All  Complication Following Ectopic Pregnancy Patients who suspected ectopic pregnancy  hemodynamically unstable patient healthy pregnancy (a healthy increase in ß HCG) missed abortion incomplete abortion The patient who need immediate surgical treatment


eligible ages (years): 18.0-50.0,  All  Ectopic Pregnancy patients with ectopic pregnancy healthy hemodynamic stable first ectopic  hemodynamic non-stable abnormal liver or kidney function allergy reaction to MTX


eligible ages (years): 18.0-65.0,  All  Type 2 Diabetes patients diagnosed as type 2 diabetes are planning to have Roux-en-Y gastric bypass age:18-65yr HbAlc>8%  diabetes (applies for control patients) chronic inflammatory disease malignant disease pregnancy prior gastric, duodenal, proximal jejunal surgery or pancreas resection current use of thiazolidinediones treatment with incretin mimetics or DPP IV inhibitors in the prior 3 months HbAlc<8% any condition felt by the investigator to interfere with ability to complete the study


eligible ages (years): 18.0-999.0,  All  Persistent Pregnancy of Unknown Location Ectopic Pregnancy Female with a persisting pregnancy of unknown location A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization Persistence of hCG is defined as at least 2 serial hCG values (over 4-14 days), showing < 50% rise, or < 50% fall between the first and last value Patient is hemodynamically stable, hemoglobin >10 mg/dL Greater than or 18 years of age  Hemodynamically unstable in need of acute treatment Most recent hCG > 5000 mIU/mL Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion) Diagnosis of gestational trophoblastic disease Subject unwilling or unable to comply with study procedures Presence of clinical contraindications for treatment with MTX Prior medical or surgical management of this gestation


eligible ages (years): 25.0-55.0,  All  Postoperative Nausea and Vomiting Patients undergoing elective laparoscopic cholecystectomy for gallstone disease Patients with age range of 25 to 55 years  H/O chronic illness like DM, IHD, CRF, CLD H/O acute or chronic psychiatric or psychological illness H/O APD (acid peptic disease) or regurgitation H/O of any chemotherapy (cancer drugs, opioids), radiotherapy, any history of repeated infection H/O use of hepatotoxic drugs like acetaminophen, ciprofloxacin, ATT, valproic acid etc. in last one month H/O alcohol intake in last one month Previous hepatobilliary surgery Complicated cholecystectomy in which laparoscopic cholecystectomy is converted to open cholecystectomy Patients who are given opioids in postoperative period Patients who need epidural analgesia in postoperative period


eligible ages (years): 30.0-50.0,  All  Obesity Overfeeding Muscle Mass Body Composition Ectopic Fat Body mass index 25-32  Type 2 diabetes Type 1 diabetes Kidney disease Liver disease Abnormal clinical chemistry at screening Intense physical exercise > 2 hours per week Use of statins or drugs affecting energy metabolism Use of extreme diets


eligible ages (years): 18.0-999.0,  All  Cholecystitis Signed informed consent All patients deemed to have a clinical and surgical indication to undergo a LESS cholecystectomy  Pregnancy Breastfeeding BMI>35 Serious comorbidities precluding a LESS cholecystectomy Known or suspected neuromuscular disorders impairing neuromuscular function Allergies to muscle relaxants, anesthetics or narcotics utilized for this study A (family) history of malignant hyperthermia A contraindication for neostigmine administration Chronic opioid use Prolonged QT syndrome


eligible ages (years): 18.0-45.0,  All  Hysteroscopic Adhesiolysis Diagnosed with intrauterine adhesions and found eligible for hysteroscopic adhesiolysis Willing to use additional contraception throughout study  Be pregnant or having a suspected molar pregnancy, lactating, or planning to become pregnant at any time during the study Has suffered or currently suffers from a gynaecological malignancy Has undergone a previous hysteroscopic surgery (such as removal of fibroids)


eligible ages (years): 18.0-40.0,  All  Vaginal Bleeding During Pregnancy Postcoital Bleeding women (age 18-40) with early pregnancy (4-23 weeks) with singleton or twins pregnancy that address to the "Women E.R." due to vaginal bleeding  age >40 or <18 women with history of more then 3 abortions women with history of more then 2 pre term labor ectopic pregnancy placental previa women who takes anticoagulation therapy women with known pathology at cervix women with known uterus defect. pregnancies with chromosomal defects or birth defects that was discovered at the screening tests


eligible ages (years): 18.0-35.0,  All  Infertility Age: between 18-35 years Period of infertility > 2 years Serum level of FSH <10 U/L in the early follicular phase All women were CC-resistant PCOS, as they failed to ovulate with a dose of CC of 150 mg/day for 5 days per cycle for at least three consecutive cycles All women had patent Fallopian tubes proved by hysterosalpingography or laparoscopy and their partners satisfied the normal parameters of semen analysis according to the modified WHO  Infertility due to causes other than CC resistant PCOS or due to combined factors Body mass index (BMI) ≥35 Kg/m² The use of metformin, gonadotropins, hormonal contraception or diet regimen within the last 6 months Women with congenital adrenal hyperplasia, hyperprolactinaemia or abnormal thyroid function Hypersensitivity or contraindications to Letrozole or clomiphene treatment Previous LOD


eligible ages (years): 18.0-40.0,  All  Infertility Pregnancy Infertile women age ranges from 18 to 40 years at the time of treatment at the MUHC reproductive centre Patients undergoing IUI Fresh and frozen sperm treatment cycles Hormone induced and natural cycle (no hormonal stimulation) Patients speaking English or/and French Patients able to consent  Patients younger than 18 years or older than 40 years of age Patients undergoing ovarian stimulation without IUI Patients who have been recruited in our study in a previous IUI cycle Patients who don't speak English or French Patients who are not able or refuse to consent Patient who are recruited in a different IUI research study


eligible ages (years): 18.0-60.0,  All  Morbid Obesity BMI >40 and < 60 kg/m2 No contraindication to any of the procedures No contraindication to general anesthesia No known addiction Patient able to provide informed consent  Contraindication to general anesthesia Known psychiatric pathology Pregnancy Previous major digestive surgery Immunosuppressive treatment including corticoids Coagulopathy (INR>1.5) or platelets < 50 000/µl Anemia (Hb<10g/dl) Severe comorbidity Malabsorptive disease or gastro-intestinal disease Myocardial infarction in previous year, angina, cardiac failure


eligible ages (years): 18.0-49.0,  All  Hysterectomy Age: 18 to 49 years at index date Gender: Female Diagnosis: Women who underwent hysteroscopic device sterilization procedure Diagnosis: Women who underwent tubal ligation sterilization procedure (includes laparoscopic tubal ligation), and salpingectomy  Patients undergoing in-vitro fertilization (IVF) procedures Embryo transfer, intrauterine Follicle puncture for oocyte retrieval, any method


eligible ages (years): 20.0-35.0,  All  Anovulation Polycystic Ovary Syndrome Age between 20-35 Primary or secondary infertility Patients diagnosed as PCOs according to Rotterdam (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.,2003)  Any patients have any causes of infertility other than which mentioned in the as Hyperprolactinemia Male factor of infertility WHO Guidelines 2010 for Normal seminal fluid analysis  Volume> 1.5 ml ph 7.2 to 8.0 Liquefaction time 20 to 30 min Sperms concentration >15 million/ml Total motility 40%(Progressive motility + non progressive motility) Progressive motility 32%


A 15 yo girl accompanied by her mother is referred for evaluation by the school. The girl has more than expected absences in the last three month, appears to be constantly tired and sleepy in class. Her mother assures the girl is well fed, and getting the proper sleep at night but admits the girls tires easily when they go out on weekend hikes. Physical examination: BP: 90/60. HR 130/min the only remarkable findings are extremely pale skin and mucosae. Grade 3/6 systolic murmur. Lab tests report Hb: 4.2 g/dL, MCV 61.8 fL, serum iron < 1.8 umol/L and ferritin of 2 ng/mL. Fecal occult blood is negative.

eligible ages (years): 0.25-9.0,  All  Anemia Age: 3 months to 9 years Haemoglobin concentration 7g/dl on admission to hospital Residence within 30 km of the study centre and availability for the duration of the study period Informed consent to participate in the study given by the parent or guardian  Simultaneous participation in any other trial Allergy to sulpha drugs Residence > 30 km from the recruitment site Lack of consent


eligible ages (years): 8.0-18.0,  All  Chest Pain 18 years of age Pediatric patients with referrals for innocent heart murmurs Pediatric patients experiencing chest pain English speaking  Non English speaking patients


eligible ages (years): 12.0-18.0,  All  Anemia Age between 12 and 18 History of Chronic Renal Failure requiring HD or PD Hgb </= 13 g/dL Ferritin < 800 ng/ml TSAT < 50% Receiving EPO  Known Sensitivity to Iron Sucrose Severe Concomitant disease of the liver or cardiovascular system Serious bacterial Infection Pregnancy / Lactation Active Hepatitis Patients with Causes of iron deficiency other that Chronic Renal Failure Blood Transfusion Body Weight < 25 KG Currently being treated for Asthma Received investigational drug within last 30 days


eligible ages (years): 0.5-12.0,  All  Sickle Cell Anemia Malaria Children aged 6 months to 12 years attending sickle cell clinic in Mulago Hospital during the study period with a negative peripheral smear for parasites, adherence to appointment visits, consent by care takers to participate in the study  Patients with known allergy to sulfonamides, Patients with severe illnesses requiring urgent admission, Patients with documented treatment for malaria in the past one month with Sulfadoxine Pyrimethamine. Patients on cotrimoxazole prophylaxis


eligible ages (years): 9.0-12.0,  All  Anaemia Schistosomiasis Infection Malaria Iron Deficiency school children between 9 to 12 year


eligible ages (years): 0.0-5.0,  All  Anaemia Age under 5 years Pregnancy Suspected anaemia


eligible ages (years): 0.538-0.654,  All  Patent Ductus Arteriosus Premature newborn infant of either gender with a birth weight of 500 to 1000 grams, appropriate for gestational age Non-symptomatic PDA with evidence of ductal shunting documented by an echocardiogram (ECHO) Less than 72 hours of age at the time of randomization If infant is one of a multiple birth, he/she is one of the two (2) oldest infants who meet the criteria Consent form signed by parent  Either major congenital malformations and/or chromosomal anomalies Proven, severe congenital bacterial infection Maternal antenatal nonsteroidal anti-inflammatory drug (NSAID) exposure < 72 hours prior to delivery Treatment with pharmacological replacement steroid therapy at anytime since birth Unremitting shock requiring very high doses of vasopressors (i.e. inability to maintain mean arterial blood pressure appropriate for gestational age ± 2 SD using volume and maximal vasopressor therapy as defined by the individual institution) Renal failure or oliguria defined as urine flow rate < 0.5 mL/kg/hr in the 8 hours prior to randomization (Anuria is acceptable if infant is in first 24 hours of life) Platelet count < 75,000/mm 3 Clinical bleeding tendency (i.e. oozing from puncture sites) Expected survival less than 48 hours in the opinion of the attending neonatologist Participation in other clinical intervention trials. Exceptions may be made if approved by Medical Director or designee, RPD Pharmaceutical Department


eligible ages (years): 1.0-6.0,  All  Malaria Anaemia All children aged 12 months to 6 years in the 13 study villages will be enrolled in the study and followed up for the duration of the study. The for randomization will be Children aged 12 months to 6 years; and History of fever in the preceding 48 hours or a measured temperature > 37.5oC plus asexual forms of P. falciparum in the peripheral blood film of 500/μl or above; and Hb <110g/l and >69g/l (Our choice of the upper limit of moderate anaemia (70 /l) is to enable us assess the response to our interventions of severer forms of anaemia while at the same time reducing the risk of adverse events which might occur with lower levels of Hb)  Refusal of parent or guardian to give consent to the child's participation in the study Inability of the subjects to take oral medications Presence of features of severe malaria as defined by WHO50, with the exception of anaemia and parasite density Children who have urgent need for blood transfusion as indicated by the presence of tachypnoea, tachycardia & gallop rhythm, tender hepatomegaly Children with known haemoglobinopathy Children with a weight for height Z score below -3SD of WHO/NCHS standard Enrolment in another research project


eligible ages (years): 5.0-999.0,  All  Sickle Cell Disease Hemolytic Anemia Established Diagnosis of Hemolysis Sickle Cell Disease (e.g., HbSS, HbS/β-thalassemia, HbSC) Other conditions with hemolysis (e.g., RBC membranopathies, enzymopathies, unstable hemoglobinopathies, PNH) Age SCD participants: 5 years of age up to 19th birthday All other participants: 5 years of age and up (no age limit)  Previous cardiac surgery Known left ventricle dysfunction (i.e. shortening fraction < 28%) Known right sided congenital heart defect such as atrial septal defect or pulmonary valve stenosis


eligible ages (years): 12.0-18.0,  All  Chronic Fatigue Syndrome Adolescents (12 years) with Chronic Fatigue Syndrome  Score greater than or equal to 44 on the Stait-Trait Anxiety Inventory for Children Score greater than or equal to 20 on the Children's Depression Inventory No availability of computer and/or internet Risk of suicide Mental retardation


eligible ages (years): 18.0-65.0,  All  Chronic Hepatitis C Male and female patients aged 18-65 years Elevated liver enzymes levels Compensated liver disease Available liver histology confirming F2 fibrosis Written consent to participation  Age <18, >65 Prior ribavirin treatment Intolerance towards ribavirin, PegIFN or erythropoetin Pregnancy or breast feeding Relevant cardiovascular or pulmonary disease Kidney insufficiency (creatinine clearance <50ml/min) Coinfection with HIV or hepatitis B virus Hepatic comorbidities (hemochromatosis, Wilson's disease, autoimmune disorders) Alcohol consumption > 40g/day Psychiatric disorders


eligible ages (years): 0.0-20.0,  All  Thalassemia Alpha Hemolytic Anemia All the patients that were studied at the pediatric hematology unit ant the Ha'Emek Medical Center


eligible ages (years): 0.0-18.0,  All  Anemia Adolescents (ages 11-18 y) and their newborns will be eligible to participate if the adolescent is carrying a singleton pregnancy, does not have any preexisting medical complications (such as HIV-infection, eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis)  Individuals with pregnancy induced hypertension or elevated diastolic blood pressure (>110) will not be eligible to participate in the study. In addition, adolescents who have been previously treated for lead exposure, or those that have been identified as having elevated blood lead concentrations during childhood, will be excluded from the study Data from infants that experience perinatal asphyxia, pathologic neonatal hyperbilirubinemia, respiratory disease, antibiotic therapy (aminoglycosides), CNS infection, sepsis, congenital or middle or external ear lesions, craniofacial anomalies, chromosomal disorders, TORCH (toxoplasmosis, other infections, rubella, cytomegalovirus infection and herpes simplex infection) or those that were clinically unstable with the first 48 h post-delivery will be excluded from ABR studies. Infants born to mothers with positive drug abuse screens at delivery will also be excluded from further study (these screens are automatically run among this age group). Infants that are identified with hearing deficits at birth using the OAE screening will be excluded from the ABR measures


eligible ages (years): 21.0-999.0,  All  Coronary Artery Disease Subjects who are undergoing routine screening coronary CT angiography Willingness to sign informed consent form  Inability to provide informed consent form Age less than 21 years Any contraindications to coronary CT angiography Known atherosclerotic heart disease, including a history of prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery or an established diagnosis of CAD by prior X-ray or CT angiography Supraventricular or ventricular arrhythmias that would be expected to affect CT-angiography image quality (e.g., atrial fibrillation, atrial flutter, ventricular tachycardia, bigeminy, and trigeminy). Patients with isolated premature atrial contractions and premature ventricular contractions may enroll Use of intravenous vasodilators Any pulmonary conditions that would create abnormal physical findings that would interfere with the fidelity of the cardiac sound recording (e.g., obstructive pulmonary disease, such as asthma or COPD, with audible wheezing) Presence of audible aortic or pulmonic diastolic murmurs, tricuspid or mitral flow diastolic murmurs, or continuous murmurs


eligible ages (years): 19.0-999.0,  All  Cardiovascular Risk Factors Age ≥ 65 years Hypertension (HTN) Diabetes Obesity (body mass index [BMI] >35) Renal insufficiency Tobacco usage Hypercholesterolemia Sleep apnea/heavy snoring at night Clinical diagnosis of CHF as defined by Dyspnea on exertion  Patients expected to say in the hospital for less than 24 hours Inability of undergo TEE and TTE Clinical evidence or suspicion of elevated intracranial pressure Preoperative shock or systemic sepsis Emergency Operation ASA Class V Inability of give informed consent Participation in another clinical trial Prisoner


eligible ages (years): 18.0-999.0,  All  Iron Deficiency Signed informed consent prior to study specific procedures Premenopausal, regularly menstruating women Age ≥18 years Body weight between 50 and 90 kg Haemoglobin ≥115 g/L Iron deficiency at screening defined as follows S-ferritin level <50 ng/mL, AND, TfS <20%, OR S-ferritin level <15 ng/mL Serum C-reactive protein <5 mg/L if not on oral contraception, OR  Haemoglobin level <115 g/L Haemoglobinopathy Haemochromatose Major depressive disorder based on Patient Health Questionnaire (PHQ-9) (5 items with scores ≥2; one of which corresponds to question number 1 or 2) Any active or unstable concurrent medical condition (e.g., cancer, renal dysfunction, liver dysfunction (aspartate aminotransferase (AST); alanine aminotransferase (ALT) >3-fold upper limit), angina (Class IV) Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection Chronic inflammatory disease (e.g., rheumatoid arthritis; inflammatory bowel disease) Documented history of clinically significant level of sleep apnoea defined as 5 or more episodes per hour of any type of apnoea Intake of concurrent medications that could interfere with physical or mental performance (e.g., antidepressive, antihistamines, narcotic or any chemotherapeutic agents known to cause drowsiness) Important recent weight loss (>10% within the past month)


eligible ages (years): 18.0-999.0,  All  Anemia, Hemolytic, Autoimmune Age 18 years or over Clinical and biochemical signs of haemolytic anaemia Positive Coombs test with anti-IgG on its own or with anti-CD3d Adequate contraceptive measures (intrauterine device, contraceptive pill or gestagen deposit) for women of childbearing potential  Performance status > 2 Previous treatment with Rituximab Other immune suppressive or anti neoplastic treatment including prednisolone within 3 months Auto immune haemolytic anaemia within 6 months Other serious disease Pregnant women and nursing mothers. Adequate contraceptive measures must be taken for the duration of the study Contraindication for treatment with Rituximab, i.e. patients that develop hypersensitivity/allergy to the contents of the drug or have antibodies against murine proteins Active infection which requires antibiotic treatment


eligible ages (years): 10.0-16.0,  All  Human Papillomavirus Infection Criteria:schoolgirls, attending the 6th and 7th grades of the elementary school  Pregnant and breastfeeding adolescents and girls who did not attend classes


eligible ages (years): 18.0-999.0,  All  Warm Autoimmune Hemolytic Anemia Age > 18 years AIHA defined at time of diagnosis by a Hgb level £ 10 g/dL, with a reticulocytes count > 120 109/L, signs of hemolysis (at least a haptoglobin level < 4 mg/L), and a positive direct antiglobulin test (DAT) ( IgG or IgG + complement pattern) Disease duration equal or less than 6 weeks at time of --> removed by amendment n°4 and substituted by :First episode of AIHA to "hot" antibody previously untreated or treated corticosteroids for less than 6 weeks Patients with an associated autoimmune thrombocytopenia (Evans' syndrome) will be eligible for the study if the platelet count is over 30 x 109/L at inclusion Normal level gammaglobulins in the serum (i.e. >5g/L) at inclusion Absence of detectable lymph nodes on a total body CT-scan (to be performed before if not performed at diagnosis) Effective means of contraception during treatment and for six months after completion of treatment for all women of child bearing age Negative serum pregnancy test within 14 days prior to study entry Written informed consent  Previous treatment with rituximab AIHA diagnosed and treated more than 6 weeks prior to removed by amendment n°4 and substituted by AIHA relapsed or newly diagnosed but treated with corticosteroids for more than 6 weeks Ongoing immunosuppressive therapy (other than corticosteroids) or previous treatment administered within 2 weeks prior to the beginning of the study treatment Non-Hodgkin Lymphoma (NHL) other than stage A chronic lymphoid leukemia Previous or concomitant malignancy other than basal cell or squamous cell carcinoma of the skin, carcinoma-in-situ of the cervix, or other malignancy for which the patient had not been disease-free for at least 5 years Autoimmune disorder such as SLE with at least one extra-hematological manifestation requiring a treatment with steroids and/or immunosuppressive drugs Any other associated cause congenital or acquired hemolytic anemia (except thalassemia trait or heterozygous sickle cell anemia) Negative DAT or DAT positive with isolated anti-C3d pattern related to the presence of a monoclonal IgM with cold agglutinin properties Positive HIV test and/or hepatitis virus C infection and/or positive hepatitis B virus surface antigen (HbsAg) Neutrophils count < 1,000/mm 3 at inclusion